Coach — DMSO (The Kit)

Kit page: DMSO is a dipolar solvent in the membrane environment mitochondria live in — not a fuel, not a miracle.

Few substances carry as much folklore as dimethyl sulfoxide. To its advocates it is a near-universal pain reliever and anti-inflammatory, a molecule that "opens membranes" and carries healing into tissue. To regulators it is a historically tainted industrial solvent with one narrow approved use and a lingering rumor about the eyes. Jugs of it sit on farm-store shelves. Both stories describe real things. Neither asks the question the working hypothesis behind this essay treats as primary: what does this molecule do to the cell's capacity to turn fuel into energy, to control the leak of reactive oxygen, and to keep intact the membranes where that work happens?

Safety first

The extended report opens with a caution: "Dimethyl sulfoxide is a biologically active solvent with a narrow and poorly mapped therapeutic window. Pharmaceutical-grade DMSO is FDA-approved in the United States only for intravesical use in interstitial cystitis. Industrial and veterinary preparations are not equivalent to pharmaceutical material and can carry contaminants across membranes. Individual responses vary widely. Readers should consult a qualified clinician before using DMSO by any route, especially in the presence of existing disease, pregnancy, eye pathology, or concurrent medications."

A few more lines stand. Industrial and veterinary DMSO is not part of this discussion in any form, and it is not something to drink or apply. This essay makes no claims about treating the eye, and nothing here is a reason to put DMSO near the eyes. It offers no topical or systemic schedule, no concentration, and no recipe. If a physician already manages an approved use, nothing here should change that plan.

Not a fuel

DMSO is a small molecule built around a strongly polarized sulfur-oxygen bond. It mixes with both water and fats, and it crosses skin, mucous membranes, the cornea, and the membranes inside cells with unusual speed. The liver converts part of it to dimethyl sulfone, sold in the supplement trade as MSM. Gut microbes and the body convert another part to dimethyl sulfide, which leaves on the breath and skin and produces the garlic or oyster odor that has done as much as any regulator to keep the compound in the realm of folklore. That odor is a metabolite. It is not proof of detoxification.

Neither product is a meaningful supply of energy. DMSO does not enter the body's energy accounts the way sugar, fat, or ketones do. In the language of this series, calories arrive wrapped in instructions. DMSO arrives wrapped in solvent physics.

The hypothesis: occupancy of the engine's housing

The hypothesis is that DMSO acts by occupying, temporarily, the watery and fatty environment in which membranes and their proteins work. Membranes are not inert bags. The inner membrane of the mitochondrion is the engine's working surface. Its curvature, thickness, hydration, and its distinctive fat, cardiolipin, decide whether electrons move through the energy chain with controlled leak or spill onto oxygen as reactive species. The thin layer of water at the membrane surface is part of that machinery.

Physical chemists have mapped what DMSO does to membranes as its concentration rises. At low levels the membrane thins. Higher, pores form. Higher still, the membrane comes apart, and at the far end membranes dehydrate. Those are not side effects. They are the primary pharmacology. Every claim made for DMSO, whether pain relief, radical scavenging, carrying other drugs, activating mitochondria, or damaging them, follows from a small solvent molecule occupying the same physical space the energy chain needs.

One curve, two ends

At the low end, the record is not uniformly hostile. In rats, DMSO raised the activity of cytochrome oxidase, the final complex of the energy chain, for several days without a matching rise in the amount of that enzyme, which points to activation through a change in the membrane rather than new enzyme being built. In older work it protected isolated mitochondria from the damage freezing normally causes, which foreshadowed its later use as a cryoprotectant for cells in laboratories. In heart-derived cells, low exposure improved one measure of mitochondrial control, though the efficiency of energy capture did not improve alongside it, a useful warning that a better-looking number is not automatically a cleaner engine.

At the high end, the literature is unambiguous. In brain support cells, exposure only modestly higher made mitochondria swell, lose their membrane voltage, leak more reactive oxygen, and release the signal that starts cell death. Higher still, the inner folds of the mitochondria disappeared and the cells died. Heart-derived cells showed the same collapse at higher exposure, erasing the benefit seen at the low end. In human muscle fibers preserved with DMSO, energy-producing capacity fell, with the first complex of the chain hit hardest, the same complex that is already the most vulnerable point in a failing chain.

Cell type matters as much as concentration. Light-sensing cells of the retina, heart muscle, endurance muscle fibers, and kidney tubule cells live near the edge of their energy budget. An exposure a cultured tumor cell tolerates may be the exposure that strips the reserve from a tissue that has none to spare. That is why a single concentration called "safe in culture" is not a biological constant, and why "more DMSO means more mitochondrial benefit" is exactly backwards.

The same curve explains sixty years of whiplash. Early clinical enthusiasm used material whose concentration at the mitochondrion was never measured. Early toxicology gave large whole-body exposures to dogs and rabbits and found changes in the lens. Both can be true. They are different points on one curve, read out in tissues of different energy demand.

Antioxidant in one regime, pro-oxidant in the next

DMSO is classically said to scavenge the hydroxyl radical, the most destructive product of iron-driven chemistry near the inner membrane. That chemistry is real. In a cell already struggling with oxidative damage to its energy chain, a brief reduction in that particular radical can look like anti-inflammatory magic: less activation of the inflammatory switches that respond to mitochondrial stress, fewer inflammatory messengers, less pain.

Once occupancy is high enough to swell the mitochondria and disorganize their folds, the same molecule helps generate reactive oxygen by wrecking the geometry of the chain that was supposed to contain it. The release of the cell-death signal is not an anti-inflammatory event. A treatment that buys pain relief by walking a tissue toward that threshold is not engine repair. "Antioxidant" is not a property of a molecule. It is a property of a molecule at a concentration, in a membrane, with a pre-existing level of leak. Any approach that cannot say which regime it occupies is not a protocol. It is a hope.

Why the dashboard seduces

Pain, swelling, and stiffness are expensive. Nerve signaling, leaky blood vessels, immune cell traffic, and the machinery of inflammation all consume energy and divert it from maintenance. This series reads much of what is called inflammation as the body spending energy it does not have because the engine cannot meet demand cleanly. A molecule that reduces that spending will feel like health even if it adds no energy at all. Pain relief, in that sense, is often a dashboard reading. The question medicine usually stops asking is whether reserve capacity, efficiency, and the honest signs of cellular fitness moved in the same direction.

The carrier property deserves the same suspicion. DMSO's ability to carry other molecules across skin and mucous membranes made it industrially useful and clinically tempting. It is also what makes industrial-grade material an uncontrolled route into the body for whatever contaminants the drum contained. A carrier can deliver a useful molecule or a toxin. A carrier is not a repair.

The one approved use, instillation into the bladder in interstitial cystitis, makes the point. There DMSO most likely acts as a local solvent and mild nerve-quieting agent on an inflamed, leaky, painful lining. That may be a rational local use. It is not evidence that DMSO restores mitochondria in heart, retina, or liver. Generalizing from that lining to the whole body is the error this essay exists to block.

The eye as canary

The retina is among the most mitochondria-dense, highest-demand tissues in the body, and the lens lives under its own long-term oxidative constraint, as discussed in the essay on the eye. Any membrane-active solvent applied there is an experiment on the canary. High-exposure lens changes in animals in the 1960s were what halted DMSO research in the United States. Later observation in people treated for other conditions did not show a clear cataract signal at the regimens then used, and the American Academy of Ophthalmology has stated that there is no reliable evidence DMSO heals cataracts, floaters, or related conditions. Both are true. They are the two ends of one curve read in a high-demand tissue.

What DMSO cannot do

DMSO does not rebuild the folds of mitochondria, restore the body's own repair chemistry, provide the adaptive stress of training, or replace honest food. It does not repair the partnership between our mitochondria and the gut community, which, in the extended report's account, both handle sulfur compounds of this family at trace levels already. A large dose is an abrupt pulse through that system, not a restoration of it. Stacking DMSO with every other supplement in this series is not a protocol. If there are rational uses at all, the hypothesis places them in brief, local, controlled settings aimed at an expensive inflammatory program in tissue that is not already near energetic failure, decided by a physician. The foundation stays the same: fuel, daily rhythm, and strength, with the essay on the immune system covering the inflammatory side.

For the full argument, read the extended report on DMSO. The short version is in the lessons. Talk with your own physician before changing medications or supplements.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.

← Kit hub · Sage depth · Surfer